An Observational study to explore the outcome of multimodal Ayurveda treatment in the management of Rheumatoid Arthritis a Prospective Cohort study.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Observing, analyse and documenting Change in CRP , ESR , RA Factor , NLR ,Uric Acid levels along with change in other objective parameters DAS28 SCORE,CDAI.
研究概览
简要总结
Rheumatoid Arthritis is a multi-system Polyarthritis connective tissue disorder causing inflammation and erosion of symmetrical smaller and larger joints characterised by pain and stiffness of synovial joints.The worldwide prevalence of the disease is approximately 1%.The disease most often affects the ages between 30 and 50 but recent studies suggests that the disease can begin in any age group.The prevalence of Rheumatoid Arthritis in India is 0.5- 3.8% in women and 0.15 - 1.35 % in men, the ratio of occurrence is 3:1.Ayurveda has mentioned classical signs and symptoms similar to RA along with various treatment principles and procedures using Panchkarma therapies and various formulations .These methods should be observed appropriately and employed in the present time to decrease the burden of disease and prevent related complications of this dreadful disease using holistic approach.Hence this study is planned to observe and document the treatment given by the Physicians in All India Institute of Ayurveda.Observation of change in subjective and objective parameters in the current clinical practise will be documented .This study provide scope for further research areas by paving a way to develop treatment protocols to tackle this dreadful Autoimmune disorder.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 21.00 Year(s) 至 65.00 Year(s)(—)
- 性别
- All
入选标准
- •The patient fulfilling Diagnostic Criteria 2010 ACR (American College of Rheumatology) /EULAR (European League Against Rheumatism) criteria for RA (min.
- •Raised level in one of the following biochemical Investigations RA Factor,CRP,Anti CCP,ESR , Serum Uric Acid.
- •Patients having classical signs and symptoms of Amavatah & Vatarakta.
排除标准
- •Patients having severe illness CAD ,respiratory failure, stroke etc.
- •Patients suffering from pre-existing systemic illnesses- CAD, uncontrolled diabetes mellitus and Hypertension , CKD, Cirrhosis, malignancies- that may jeopardise the treatment outcomes.
- •Patients taking DMARDs and Biologicals during the intervention period.
- •Patients having co-existing Autoimmune conditions – SLE, Spondyloarthropathy, scleroderma .
- •Pregnant women and lactating mother.
结局指标
主要结局
Observing, analyse and documenting Change in CRP , ESR , RA Factor , NLR ,Uric Acid levels along with change in other objective parameters DAS28 SCORE,CDAI.
时间窗: Day 0 | Day 15 | Day 30 | Day 45 | Day 60 | Day 120
Observe the Change in Clinical symptomatology of the RA patients.
时间窗: Day 0 | Day 15 | Day 30 | Day 45 | Day 60 | Day 120
次要结局
- Observing Change in Qualty of Life of RA affected individuals.(Day 0)
研究者
Naveen Kumar
All India Institute of Ayurveda
